ClinicalTrials.gg
RecruitingNCT04715659Updated May 9, 2023

A Novel Incremental Step Test as an Alternative for the Assessment of Exercise Capacity in Patients With COPD

An observational study in COPD, sponsored by Polytechnic Institute of Porto. Recruiting at 1 site in Portugal. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2023-05-09.

Sponsored by Polytechnic Institute of Porto · Observational

From the registry’s dates

  • Started Jan 2021; still recruiting 5 years 10 months later.
Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
50
Ages
18 Years to 90 Years
Sex
All
01

Study summary

According to the official guidelines of pulmonary rehabilitation, a structured home-based approach is recommended to answer to the inadequate number of pulmonary rehabilitation services due to the chronic obstructive pulmonary disease (COPD) patient's needs. For this new setting, new strategies for the assessment of exercise capacity and exercise training are essential. The modality of step can be a promising tool because it is inexpensive, portable, and reflects one of the main activities of daily living (stair climbing). The development of a new field test implies the study of the measurement properties, to facilitate the selection of tests and the interpretation of the results in rehabilitation. This project hypothesizes that the step test can be valid, reliable, and feasible to apply in this new setting of pulmonary rehabilitation.

Read the detailed description

The primary aim of this project is to develop and determine the measurement properties (validity and reliability) of a novel step test for the assessment of exercise capacity in patients with COPD.

The investigators will perform two cross-sectional studies for validity and reliability in patients with COPD. Participants attending a pneumology consultation at the hospital will be asked for permission to be contacted about the study. The participants who agree will be seen by the principal investigator who will explain the nature of the study and assess eligibility for the study. The participants will sign informed consent.

The validity study will be performed in two days (separated >48h). During the first session, the participants will perform the 6-minute walk test (6MWT) twice (a valid test for COPD). On the second day, the step test will be performed twice.

The reliability study will be performed in two days (separated for 7 days). On both days, the step test will be performed one time.

The investigators predict that 50 patients with COPD will be followed in each study (validity and reliability).

The investigators hypothesize that the step test can be a good option to apply in pulmonary rehabilitation programs with good measurement properties for the assessment of exercise capacity in COPD patients. The validation of the test can contribute to applying the step modality in the exercise training as an alternative for the prescription of the exercise intensity. For that, the investigators also hypothesize that the test can be reliable and one test must be enough for the assessment of the patients.

02

Conditions studied

  • COPD

Keywords

  • validity
  • reliability
  • pulmonary rehabilitation
03

In context

Pulmonary Disease, Chronic Obstructive

5,520 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

This study's planned enrollment of 50 is below the median of 158 across 1,497 observational studies indexed under Pulmonary Disease, Chronic Obstructive.

Browse Pulmonary Disease, Chronic Obstructive studies →

Lead sponsor

Polytechnic Institute of Porto is the lead sponsor of 14 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients attending a pneumology consultation at the hospital will be asked for permission to be contacted about the study. Those who agree will be seen by the principal investigator who will explain the nature of the study and assess eligibility for the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients are eligible with a diagnose of (COPD).

Exclusion criteria

Exclusion Criteria:

  • Patients will be excluded if they have a significant cardiac, immune, musculoskeletal or neurological impairment, or any other that does not allow them to perform the tests.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • COPD patients

    Diagnostic Test: Performance of step test (number of steps) for the assessment of exercise capacity

Interventions

  • Diagnostic testPerformance of step test (number of steps) for the assessment of exercise capacity

    The development of the step test will be designed according to the characteristics of other validated field tests - the walking tests (6-minute walk test and the incremental shuttle walking test) The step test will be performed on a 20 cm tall, single-step device with no handles. The criteria for stopping the test will be the same as described in standard operating procedures for the walking field tests, with the addition of the inability to follow the work rate for a period of 10 seconds. The main outcome of the test will be the highest number of steps and work rate achieved.

06

What researchers measure

Primary outcomes

  1. Number of steps

    The primary outcome will be the amount of the number of steps performed in the step test

    Time frame: Through test completion, duration of the test 15 minutes

  2. Distance walked

    The primary outcome will be the distance walked performed in the 6-minute walk test

    Time frame: Through test completion, duration of the test 6 minutes

  3. Distance walked

    The primary outcome will be the distance walked performed in the incremental shuttle walk test

    Time frame: Through test completion, duration of the test 12 minutes

Secondary outcomes

  1. Dyspnea during the tests

    Dyspnea experienced during the tests, monitored with the modified Borg scale, that ranges from 0 to 10, where 0 represents no dyspnea and 10 the worst dyspnea.

    Time frame: Through test completion, duration of the tests 6 and 15 minutes

  2. Fatigue during the tests

    Fatigue experienced during the tests, monitored with the modified Borg scale, that ranges from 0 to 10, where 0 represents no fatigue and 10 the worst fatigue

    Time frame: Through test completion, duration of the tests 6 and 15 minutes

  3. Heart rate during the tests

    Heart rate assessed during the tests, monitored with a cardiofrequencimeter

    Time frame: Through test completion, duration of the tests 6 and 15 minutes

  4. Oxygen saturation during the tests

    Oxygen saturation assessed during the tests, monitored with a pulse oximeter

    Time frame: Through test completion, duration of the tests 6 and 15 minutes

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Vilarinho R, Serra L, Aguas A, Alves C, Silva PM, Caneiras C, Montes AM. Validity and reliability of a new incremental step test for people with chronic obstructive pulmonary disease. BMJ Open Respir Res. 2022 Apr;9(1):e001158. doi: 10.1136/bmjresp-2021-001158. PubMed 35387847 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04715659
Lead sponsor
Polytechnic Institute of Porto
Collaborators
Nippon Gases Portugal
Responsible party
Rui Vilarinho (Professor, Polytechnic Institute of Porto) — Principal investigator
First posted
Jan 20, 2021
Start date
Jan 4, 2021
Primary completion
Jul 30, 2021
Completion
Dec 31, 2023 (estimated)
Last update
May 9, 2023

Study contacts

Rui A Vilarinho, Master
Contact
rav@ess.ipp.pt
222061000 ext. +351

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion